来源：雅虎金融 2019-03-19 22:21Today, I’d like to discuss the outlook for AbbVie (NYSE:ABBV), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been ham
来源：Reuters 2019-03-19 21:01March 19 (Reuters) - AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer treatment Venclexta for multiple myeloma.The partial ho
来源：DowjonesNews 2019-03-19 20:52MWAbbVie'sstockfalls0.8%premarketafterFDAplacesholdontrialofmultiplemyelomatreatment(END)DowJonesNewswiresMarch19,201908:52ET(12:52GMT)Copyright(c)2019DowJones&Company,Inc.
来源：DowjonesNews 2019-03-19 20:51MWAbbViesaysFDAholdfollowsreviewoftrialdatashowinghigherproportionofdeaths(END)DowJonesNewswiresMarch19,201908:51ET(12:51GMT)Copyright(c)2019DowJones&Company,Inc.
来源：DowjonesNews 2019-03-19 20:50MWAbbViesaidFDAplacea'partialclinicalhold'ontrialsevaluatingmyelomatreatment(END)DowJonesNewswiresMarch19,201908:50ET(12:50GMT)Copyright(c)2019DowJones&Company,Inc.
来源：StreetInsider 2019-03-19 20:46AbbVie(NYSE:ABBV),aresearch-basedglobalbiopharmaceuticalcompany,todayannouncedtheU.S.FoodandDrugAdministration(FDA)hasplacedapartialclinicalholdonallclinicaltrialsevaluatingvenetoclax(VENCLEXTA®/VENCL
来源：PR Newswire 2019-03-19 20:45NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial c
来源：Zacks 2019-03-19 05:45AbbVie (ABBV) closed the most recent trading day at $80.65, moving -0.85% from the previous trading session. This move lagged the S&P 500's daily gain of 0.37%. At the same time, the Dow added 0.25%,
来源：sina 2019-03-19 01:36DJBigPharmaEarningsMightNotBeasGoodasTheyLook--Barrons.comByAviSalzmanBigdrugcompanieshaveincreasinglybeenreleasingfinancialnumbersthatusenonstandardaccounting,andthathasatleastoneanalystonedge.Twocom
来源：Motley Fool 2019-03-17 21:03AbbVie (NYSE: ABBV) has seen better days. After a 54% gain in 2017, the big-pharma stock lost ground last year. So far in 2019, AbbVie's share price has fallen by a double-digit percentage.Are investo
来源：Zacks 2019-03-14 22:36Roche RHHBY announced that the European Commission (EC) has approved a label expansion of hemophilia drug, Hemlibra (emicizumab).The drug is now approved for routine prophylaxis of bleeding episodes i
来源：Motley Fool 2019-03-14 21:14Dividend Aristocrats -- or companies that have raised their dividends for a minimum of 25 consecutive years -- are always worth considering as long-term investing vehicles. These elite income stocks,
来源：MoneyShow 2019-03-14 18:00Our The Timely Ten list represents our top ten current recommendations from among our universe of undervalued blue chip stocks, explains dividend expert Kelley Wright, editor of the industry-leading a
来源：Zacks 2019-03-14 02:27Theravance Biopharma, Inc. TBPH has dosed the first patient in a phase IIb/III study on its gut-selective pan-Janus kinase (JAK) inhibitor, TD-1473 in patients with moderately to severely active ulcer
来源：Yahoo Finance 2019-03-13 20:37Pharmaceutical companies have been under the spotlight as of recently, due to congressional hearings on the cost of drug prices and allegations of the industry’s role in the opioid crisis.Dr. Raeford